(Reuters) -Shares of weight-loss drug developer Metsera surged nearly 42% in a strong Nasdaq debut on Friday, valuing the ARCH Venture Partners-backed biotech firm at $2.68 billion. Shares of the ...

These compounds take a different approach to weight loss than existing medications, which can cause nausea, vomiting and ...

Shares of weight-loss drug developer Metsera jumped nearly 42% in a strong Nasdaq debut on Friday, valuing the ARCH Venture ...

Cost is a major obstacle for many. The drugs can be expensive without insurance, with out-of-pocket expenses reaching ...

New poll shows about half of U.S. adults believe it is a good thing for adults to use weight-loss drugs if they are ...

Echoing Iselin's assessment, Fallon Health CEO Manny Lopes said both providers and payers are at a "crisis point." Meanwhile, ...

Police boats have returned to the Potomac River as part of the recovery and investigation after the United States’ deadliest ...

Eli Lilly achieved the largest market capitalisation growth of 32.4% to $733bn in 2024, driven by strong demand for Mounjaro ...

Approximately 15.5 million Americans have been or currently are on injectable diabetes or weight-loss medications known as ...

Analysts predict the weight loss drug market to grow between $100 billion and $130 billion by 2030, as per a report.

Telehealth company Him & Hers Health is taking a very different approach to its Super Bowl ad this year - as its new ...